Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Гиперпролактинемия

Литература.

  1. Дедов И.И., Мельниченко Г.А., Романцова Т.И. Синдром гиперпролактинемии. М: Триада 2004; 304.
  2. Дедов И.И., Мельниченко Г.А., Романцова Т.И., Рожинская Л.Я., Дзеранова Л.К., Иловайская И.А., Далантаева Н.С., Бармина И.И. Гиперпролактинемия. Современные подходы и старые проблемы. Вестник репродуктивного здоровья. 2009; 2: 2-8.
  3. Дзеранова Л.К., Табеева К.И., Гончаров Н.П., Колесникова Г.С, Добрачева А.Д. Макропролактинемия. Проблемы репродукции. 2005;11(2): 60-65.
  4. Мельниченко Г.А., Марова Е.И., Дзеранова Л.К., Вакс В.В. Гиперпролактинемия у женщин и мужчин: Пособие для врачей. М. 2008.
  5. Иловайская И.А. Диагностика и лечение гиперпролактинемии: клинические рекомендации Международного эндокринологического общества и взгляд российских экспертов. Акушерство и гинекология 2012; 1: 2-7.
  6. Клиническая нейроэндокринология. Под ред. И.И. Дедова. М 2011; 113-118.
  7. Ларина А.А., Григорян О.Р., Андреева Е.Н., Дзеранова Л.К. Гиперпролактинемия и беременность. Проблемы репродукции. 2013. № 3. С. 13-17
  8. Klibanski A. Prolactinomas. N Engl J Med. 2010; 362: 1219-26.
  9. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, MontoriVM, Schlechte JA et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline. JClin Endocrinol Metab. 2011; 96: 273-88.
  10. Casanueva F, Molitch M, Schlechte J, Abs R, Bonert V, Bronstein MD, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf). 2006; 65: 265-73.
  11. Petakov MS, Damjanovia SS, Nikolia-Durovia MM, Dragojlovia ZL,Obradovia S, Gligorovia MS, et al. Pituitary adenomas secreting large amounts of prolactin may give false low values ininmunoradiometric assays. The hook effect. J Endocrinol Invest.1998; 21: 184-8.
  12. McKenna TJ. Should macroprolactin be measured in all hyperprolactinaemic sera? Clin Endocrinol (Oxf). 2009; 71: 466-9.
  13. Gibney J, Smith TP, Mac Kenn TJ. The impact on clinical practice of routine screening for macroprolactin. J Clin Endocrinol Metab. 2005; 90: 3927-32.
  14. Molitch ME. Medication-induced hyperprolactinemia. Mayo ClinProc. 2005; 80: 1050.
  15. Famini P, Maya MM, Melmed S. Pituitary magnetic resonance imaging for sellar and parasellar masses: ten-year experience in 2598 patients. J Clin Endocrinol Metab. 2011; 96: 1633-41.
  16. Ikeda H, Abe T, Watanaba K. Usefulness of composite methionine-positron emission tomography/3.0-tesla magnetic resonance imaging to detect the localization and extent of early-stage Cushing adenoma. J Neurosurg. 2010; 112: 750-5.
  17. Elston MS, McDonald KL, Clifton-Bligh RJ, Robinson BG. Familial pituitary tumor syndromes. Nat Rev Endocrinol. 2009; 5: 453-61.
  18. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev. 2006; 27: 485-534.
  19. Schlechte J, Dolan K, Sherman B, Clapler F, Luciano A. The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab. 1989; 68: 412-8.
  20. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med. 1994; 331: 904-9.
  21. Leong KS, Foy PM, Swift AC, Atkin SL, Hadden DR, Mac Farlane IA. CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas. Clin Endocrinol (Oxf).2000; 52: 43-9.
  22. Iyer P, Molitch ME. Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas. EndocrPract. 2011; 17: 55-8.
  23. Ono M, Miki N, Kawamata T, Makino R, Amano K, Seki T,et al. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab.2008; 93: 4721-7.
  24. Delgrange E, Daems T, Verhelst J, Abs R, Maiter D. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. EurJ Endocrinol. 2009; 160: 747-52.
  25. Herring N, Szmigielski C, Becher H, Karavitaki N, Wass JA. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol (Oxf). 2009; 70: 104-8.
  26. Vallette S, Serri K, Rivera J, Santagata P, Delorme S, Garfield N, et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary.2009; 12: 153-7
  27. Wakil A, Rigby AS, Clark AL, Kallvikbacka-Bennett A, Atkin SL. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol. 2008; 159: 11-4.
  28. Valassi E, Klibanski A, Biller BMK. Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metab. 2010; 95: 1025-33.
  29. Klibanski A. Dopamine agonist therapy in prolactinomas: when can treatment be discontinued. J Clin Endocrinol Metab.2009; 94: 2247-9.
  30. Barber TM, Kenkre J, Garnett C, Scott RV, Byrne JV, Wass JAH. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy with prolactinoma occurs commonly specially in macroprolactinoma. Clin Endocrinol (Oxf).2011; 75: 819-24.
  31. Ciccarelli E, Grottoli S, Razzore P, Gaia D, Bertagna A, Cirillo S, et al. Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumourous hyperprolactinaemia and outcome of drug-induced pregnancy. J Endocrinol Invest. 1997; 20: 547-51.
  32. Barker II FG, Klibanski A, Swearingen B. Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume. JClin Endocrinol Metab. 2003; 88: 4709-19.
  33. Soule SG, Farhi J, Conway GS, Jacobs HS, Powell M. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy. Clin Endocrinol (Oxf). 1996; 44: 711-6.
  34. Babey M, Sahli R, Vajtai I, Andres RH, Seiler RW. Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonist. Pituitary. 2011;14:222-30.
  35. Amar AP, Couldwell WT, Chen JC, Weiss MH. Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery. J Neurosurg. 2002; 97: 307-14.
  36. Massoud F, Serri O, Hardy J, Somma M, Beauregard H. Transsphenoidal adenomectomy for microprolactinomas: 10-20 years of follow-up. Surg Neurol. 1996; 45: 341-6.
  37. Tanaka S, Link MJ, Brown PD, Stafford SL, Young WF, Pollock BE. Gamma knife radiosurgery for patients with prolactin-secreting pituitary adenomas. World Neurosurg. 2010; 74: 147-52.
  38. Brada M, Ajiyhkumar TV, Minniti C. Radiosurgery for pituitary adenomas. Clin Endocrinol (Oxf). 2004; 61: 531-4.
  39. Molitch M. Prolactinomas and pregnancy. Clin Endocrinol (Oxf).2010; 73: 147-8.
  40. Gonzalez JG, Elizondo G, Saldivar D, Nanez H, Todd LE, Villarreal JZ. Pituitary gland growth during normal pregnancy: in vivo study using magnetic resonance imaging. Am J Med.1988; 85: 217-20.
  41. Colao A, Abs R, Barcena DG, Chanson P, Paulus W, Kleinberg DL. Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clin Endocrinol(Oxf). 2008; 68: 66-71.
  42. Stalldecker G, Mallea-Gil MS, Guitelman M, Alfieri A, Ballarino MC, Boero L, et al. Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103pregnancies and a review of the literature. Pituitary. 2010; 1: 345-50.
  43. Colao A, Loche S. Prolactinomas in children and adolescents. Endocr Dev Basel Karger. 2010; 17: 146-59.
  44. Karunakaran S, Page RC, Wass JA. The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clin Endocrinol (Oxf). 2001; 54: 295-300.
  45. Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1antibody. Neurosurgery. 2004; 61: 111-6.
  46. Lim S, Shahinian H, Maya MM, Yong W, Heaney AP. Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol.2006; 7: 518-20.
  47. Cormack AI, McDonald KL, Gill AJ, Clark SJ, Burt MG, Campbell KA, et al. Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf). 2009; 71: 226-33.
  48. Luque GM, Pérez-Millán MI, Ornstein AM, Cristina C, Becu-Villalobos D. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas. J Pharmacol Exp Ther. 2011; 337: 766-74.
  49. Lau Q, Scheithauer B, Kovacs K, Horvath E, Syro LV, Lloyd R.MGMT immunoexpression in aggressive pituitary adenoma and carcinoma. Pituitary. 2010; 13: 367-79.

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

Литература.
На предыдущую главу Предыдущая глава
оглавление
Следующая глава

Table of contents

Данный блок поддерживает скрол*